Valneva GMP manufacturing operations cover the internal and external production of clinical and commercial products.
Vaccine manufacturing is considered to be extremely demanding: Valneva’s production facilities operate according to high quality standards, which are regularly and rigorously verified by Valneva’s partners and by multiple regulatory authorities.
Valneva's manufacturing plant in Livingston is currently dedicated to the production of the company’s leading product, IXIARO®/JESPECT®, a vaccine indicated for the prevention of Japanese encephalitis.
The modern production facility with an installed capacity of more than 1.5 million doses fulfills all cGMP requirements and provides for a very efficient production process.
Valneva manufactures the cholera vaccine DUKORAL® at its fully owned site in Solna, Sweden. The Solna site has been a Valneva-owned entity since its acquisition in 2015 and includes facilities for viral as well as bacterial vaccine production. The facility operates under respective manufacturing licenses from the Swedish Medical Products Agency (MPA) with an installed capacity of more than 2.5 million doses.